EPIC-STI PROJECT 2 (CHACKERIAN): Discovery and Refinement of Preventive STI Vaccines Targeting Critical Epitopes of Human Papillomaviruses and Chlamydia trachomatis SUMMARY Human Papillomavirus (HPV) and Chlamydia trachomatis (CT) are the two most common sexually transmitted infections (STIs) worldwide. HPV is the etiological agent of virtually all cases of cervical cancer and a large percentage of other cancers of the urogenital tract. Untreated CT infection of the genital tract can cause significant acute symptoms as well as longer term complications, including pelvic inflammatory disease (PID) and infertility. The goal of this project in the Epidemiology and Prevention Interdisciplinary Center (EPIC) for Sexually Transmitted Infections (EPIC-STI) is to develop effective broadly effective vaccines targeting these two important STIs. We have developed a Virus-like Particle (VLP) based peptide display and affinity selection platform. This platform integrates the potent immunogenicity of VLP display with an affinity selection capability that allows the identification of vaccine candidates by two complementary methods. First, we can engineer the VLPs to display specific targets in a highly multivalent format that renders the target potently immunogenic. We have this approach to develop a second generation, broadly neutralizing HPV vaccine that is capable of blocking infection by all of the HPV types associated with cervical cancer, not just the two types targeted by the current vaccine. Second, we can use the VLP platform to identify vaccines from large libraries of potential vaccines by affinity selection using antibodies. In this project, we will use this approach to map epitopes targeted by the natural antibody response to CT infection, with the goal of identifying potential prophylactic CT vaccines. This project will draw heavily of biostatistics and bioinformatics facilities provided by Core B and will have significant synergy with Project 3 (Gravitt) and Project 1 (Starnbach).
- EPIC-STI PROJECT 2 (CHACKERIAN) Project 2 will apply a recently developed system for peptide display and affinity selection using virus-like particles of the RNA bacteriophage MS2 to further develop a candidate second-generation Human Papillomavirus vaccine and to identify potential vaccines for Chlamydia trachomatis.
|Lijek, Rebeccah S; Helble, Jennifer D; Olive, Andrew J et al. (2018) Pathology after Chlamydia trachomatis infection is driven by nonprotective immune cells that are distinct from protective populations. Proc Natl Acad Sci U S A 115:2216-2221|
|Frietze, Kathryn M; Lijek, Rebeccah; Chackerian, Bryce (2018) Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis. Expert Rev Vaccines 17:959-966|
|Yokoyama, Christine C; Baldridge, Megan T; Leung, Daisy W et al. (2018) LysMD3 is a type II membrane protein without an in vivo role in the response to a range of pathogens. J Biol Chem 293:6022-6038|
|Castle, Philip E; Wheeler, Cosette M; Campos, Nicole G et al. (2018) Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Prev Med 111:177-179|
|Arrossi, Silvina; Temin, Sarah; Garland, Suzanne et al. (2017) Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline. J Glob Oncol 3:611-634|
|Zhai, Lukai; Peabody, Julianne; Pang, Yuk-Ying Susana et al. (2017) A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. Antiviral Res 147:116-123|
|Ramírez-Peinado, Silvia; Ignashkova, Tatiana I; van Raam, Bram J et al. (2017) TRAPPC13 modulates autophagy and the response to Golgi stress. J Cell Sci 130:2251-2265|
|Cuzick, Jack; Myers, Orrin; Lee, Ji-Hyun et al. (2017) Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. JAMA Oncol 3:1327-1334|
|Peabody, Julianne; Muttil, Pavan; Chackerian, Bryce et al. (2017) Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature. Papillomavirus Res 3:116-120|
|Laborde, Rady J; Sanchez-Ferras, Oraly; Luzardo, María C et al. (2017) Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response. J Immunol 198:2772-2784|
Showing the most recent 10 out of 18 publications